11:08 AM EST, 11/10/2026 (MT Newswires) -- (Updates with Eli Lilly's statement) The US Food and Drug Administration is mandating that manufacturers of glucagon-like peptide-1 receptor agonist, or GLP-1 RA, medications update product labels to warn of a potential increased risk of non-arteritic anterior ischemic optic neuropathy, a rare but serious eye condition. The regulator advised patients and healthcare providers to be aware of the potential risk associated with the use of GLP-1 RAs, which are widely used to treat people with type 2 diabetes or to lose weight, according to a Monday notice. Novo Nordisk (NOVO-B.CO) and Eli Lilly (LLY.F, LLY.SW) are among the drugmakers with FDA-approved GLP-1 RAs. "Patient safety is Lilly's top priority. FDA's drug safety communication applies to all medicines with GLP-1 RA activity and does not reference any findings specific to Lilly medicines. We are carefully evaluating the update and will respond to FDA promptly. As always, we will remain in close contact with the agency and continue to review all available data, including any data regarding ophthalmic events," a Lilly spokesperson told MT Newswires. Novo Nordisk did not immediately respond to a request for comment.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.